|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003241,
umls-concept:C0024518,
umls-concept:C0039194,
umls-concept:C0456387,
umls-concept:C0596402,
umls-concept:C1327413,
umls-concept:C1332709,
umls-concept:C1514562,
umls-concept:C1880389,
umls-concept:C1883204,
umls-concept:C1883221,
umls-concept:C2349975
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2005-6-9
|
|
pubmed:abstractText |
T cells require both primary and costimulatory signals for optimal activation. The primary Ag-specific signal is delivered by engagement of the TCR. The second Ag-independent costimulatory signal is mediated by engagement of the T cell surface costimulatory molecule CD28 with its target cell ligand B7. However, many tumor cells do not express these costimulatory molecules. We previously constructed phage display derived F(AB), G8, and Hyb3, Ab-based receptors with identical specificity but distinct affinities for HLA-A1/MAGE-A1, i.e., "TCR-like" specificity. These chimeric receptors comprised the FcepsilonRI-gamma signaling element. We analyzed whether linking the CD28 costimulation structure to it (gamma + CD28) could affect the levels of MHC-restricted cytolysis and/or cytokine production. Human scFv-G8(POS) T lymphocytes comprising the gamma + CD28 vs the gamma signaling element alone produced substantially more IL-2, TNF-alpha, and IFN-gamma in response to HLA-A1/MAGE-A1(POS) melanoma cells. Also a drastic increase in cytolytic capacity of scFv-G8(POS) T cells, equipped with gamma + CD28 vs the gamma-chain alone was observed.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD28,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Cytokines,
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes, T-Lymphocyte,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A1 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Fab Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Variable Region,
http://linkedlifedata.com/resource/pubmed/chemical/Melanoma-Specific Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Antigen, T-Cell,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, IgE
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0022-1767
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
174
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7853-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15944290-Adjuvants, Immunologic,
pubmed-meshheading:15944290-Antigens, CD28,
pubmed-meshheading:15944290-Antigens, Neoplasm,
pubmed-meshheading:15944290-Binding Sites, Antibody,
pubmed-meshheading:15944290-Cell Line, Tumor,
pubmed-meshheading:15944290-Cytokines,
pubmed-meshheading:15944290-Cytotoxicity, Immunologic,
pubmed-meshheading:15944290-Epitopes, T-Lymphocyte,
pubmed-meshheading:15944290-HLA-A1 Antigen,
pubmed-meshheading:15944290-Humans,
pubmed-meshheading:15944290-Immunoglobulin Fab Fragments,
pubmed-meshheading:15944290-Immunoglobulin Variable Region,
pubmed-meshheading:15944290-K562 Cells,
pubmed-meshheading:15944290-Lymphocyte Activation,
pubmed-meshheading:15944290-Melanoma,
pubmed-meshheading:15944290-Melanoma-Specific Antigens,
pubmed-meshheading:15944290-Neoplasm Proteins,
pubmed-meshheading:15944290-Protein Structure, Tertiary,
pubmed-meshheading:15944290-Receptors, Antigen, T-Cell,
pubmed-meshheading:15944290-Receptors, IgE,
pubmed-meshheading:15944290-Signal Transduction,
pubmed-meshheading:15944290-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:15944290-Transduction, Genetic
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production.
|
|
pubmed:affiliation |
Laboratory of Tumor Immunology, Department of Medical Oncology, Erasmus Medisch Centrum Daniel den hoed, Rotterdam, The Netherlands. r.a.willemsen@erasmusmc.nl
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
